Skip to content

SGE Smoking Cessation Innovation.

Stichting Gezondheidscentra Eindhoven Smoking Cessation Innovation.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23449
Enrollment
272
Registered
2011-09-14
Start date
2011-09-20
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Smoking cessation Varenicline Practice nurse Intensive counselling Health care innovation

Interventions

Participants in the intervention group recieve intensive counselling from a practice nurse in combination with 12-weeks varenicline. The intensive counselling consists of three individual face-to-face

Sponsors

D. Kotz Research Institute CAPHRI, Department of General Practice, Maastricht University P. Debyeplein 1, 6229 HA, Maastricht P.O. Box 616, 6200 MD Maastricht, The Netherlands T 043-3882893 F 043-3619344
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: We aim to recruit those adult smokers into the trial who normally consult with their general practitioner in primary care.

Exclusion criteria

Exclusion criteria: Participants are excluded from the study when they: 1. Do not smoke daily; 2. Are younger than 18 years; 3. Are unable to understand Dutch sufficiently.

Design outcomes

Primary

MeasureTime frame
Prolonged smoking abstinence from week 9 to week 26. Smoking abstinence will be validated by measuring exhaled carbon monoxide (CO) in all self-reported non-smokers.

Secondary

MeasureTime frame
The secondary outcome parameters are: 1. Cost-effectiveness of the two smoking cessation treatments, expressed as the intervention costs per quitter; 2. Compliance with varenicline in both treatment groups.

Contacts

Public ContactC. Rossem, van

P.O. Box 616

carolien.vanrossem@maastrichtuniversity.nl+31 (0)43 38882202

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)